Isonicotinamide structure
|
Common Name | Isonicotinamide | ||
|---|---|---|---|---|
| CAS Number | 1453-82-3 | Molecular Weight | 122.13 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 334.4±15.0 °C at 760 mmHg | |
| Molecular Formula | C6H6N2O | Melting Point | 155-157 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 156.0±20.4 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of IsonicotinamideIsonicotinamide is a biochemical reagent that can be used as a biological material or organic compound for life science related research. |
| Name | isonicotinamide |
|---|---|
| Synonym | More Synonyms |
| Description | Isonicotinamide is a biochemical reagent that can be used as a biological material or organic compound for life science related research. |
|---|---|
| Related Catalog |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 334.4±15.0 °C at 760 mmHg |
| Melting Point | 155-157 °C(lit.) |
| Molecular Formula | C6H6N2O |
| Molecular Weight | 122.13 |
| Flash Point | 156.0±20.4 °C |
| Exact Mass | 122.048012 |
| PSA | 55.98000 |
| LogP | -0.28 |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.570 |
| InChIKey | VFQXVTODMYMSMJ-UHFFFAOYSA-N |
| SMILES | NC(=O)c1ccncc1 |
| Water Solubility | 191.7 g/L (37 ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATAMUTATION DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi:Irritant |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | NR9500000 |
| HS Code | 29333999 |
| Precursor 10 | |
|---|---|
| DownStream 10 | |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Br. J. Cancer 111(3) , 477-85, (2014) Current therapies for metastatic melanoma are targeted either at cancer mutations driving growth (e.g., vemurafenib) or immune-based therapies (e.g., ipilimumab). Tumour progression also requires angi... |
|
|
[Fe(CN)5(isoniazid)](3-): an iron isoniazid complex with redox behavior implicated in tuberculosis therapy.
J. Inorg. Biochem. 140 , 236-44, (2014) Tuberculosis has re-emerged as a worldwide threat, which has motivated the development of new drugs. The antituberculosis complex Na3[Fe(CN)5(isoniazid)] (IQG607) in particular is of interest on accou... |
|
|
Measuring induction times and crystal nucleation rates.
Faraday Discuss. 179 , 199-214, (2015) A large variation is observed in induction times measured under equal conditions in 1 ml solutions. Ruling out experimental errors, this variation originates from the nucleation process. The induction... |
| 4-Pyridine carboxamide |
| MFCD00006432 |
| 4-pyridinecarboximidic acid |
| 4-Pyridinecarboxamide |
| EINECS 215-926-2 |
| 4-(HYDROXYIMINOMETHYL)PYRIDINE |
| Isonicotinamide |
| Pyridine-4-carboximidic acid |
| pyridine-4-carboxamide |